TEVA · Teva Pharmaceutical Industries Ltd
$37.61
-0.31 (-0.82%)
At close · Aug 27
Market Cap
$44.19B
Shares
1.17B
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 8-K | 2026-07-29 | — | |
| 10-Q | 2026-07-29 | 2026-06-30 | |
| Investor Event Transcript | 2026-06-08 | 2026-06-30 | |
| 8-K | 2026-05-28 | — | |
| 10-Q | 2026-04-29 | 2026-03-31 | |
| 8-K | 2026-04-29 | — | |
| Investor Event Transcript | 2026-03-31 | — | |
| DEF 14A | 2026-03-31 | 2026-05-28 | |
| 10-K | 2026-02-03 | 2025-12-31 | |
| 8-K | 2026-01-28 | — | |
| 8-K | 2026-01-12 | 2026-01-11 | |
| 8-K | 2025-12-11 | 2025-12-10 | |
| 10-Q | 2025-11-05 | 2025-09-30 | |
| 8-K | 2025-11-05 | — | |
| 8-K | 2025-07-30 | — | |
| 10-Q | 2025-07-30 | 2025-06-30 | |
| 8-K | 2025-06-05 | — | |
| 8-K | 2025-05-28 | — | |
| 8-K | 2025-05-22 | 2025-05-20 | |
| 8-K | 2025-05-07 | — | |
| 10-Q | 2025-05-07 | 2025-03-31 | |
| DEF 14A | 2025-04-09 | 2025-06-05 | |
| Investor Event Transcript | 2025-02-24 | 2025-03-31 | |
| 10-K | 2025-02-05 | 2024-12-31 | |
| 8-K | 2025-01-29 | — | |
| 8-K | 2024-11-12 | 2024-11-05 | |
| 8-K | 2024-11-06 | — | |
| 10-Q | 2024-11-06 | 2024-09-30 | |
| 10-Q | 2024-07-31 | 2024-06-30 | |
| 8-K | 2024-07-31 | — | |
| 8-K | 2024-06-25 | 2024-06-23 | |
| 8-K | 2024-06-06 | — | |
| 8-K | 2024-05-15 | — | |
| 10-Q | 2024-05-08 | 2024-03-31 | |
| 8-K | 2024-05-08 | — | |
| 8-K | 2024-04-18 | — | |
| DEF 14A | 2024-04-16 | 2024-06-06 | |
| 10-K | 2024-02-12 | 2023-12-31 | |
| 8-K | 2024-01-31 | — | |
| 10-Q | 2023-11-09 | 2023-09-30 | |
| 8-K | 2023-11-08 | — | |
| 8-K | 2023-10-04 | — | |
| 8-K | 2023-09-28 | 2023-09-25 | |
| 8-K | 2023-08-24 | 2023-08-21 | |
| 8-K | 2023-08-02 | — | |
| 10-Q | 2023-08-02 | 2023-06-30 | |
| 8-K | 2023-08-02 | 2023-08-01 | |
| 8-K | 2023-06-15 | — | |
| 8-K | 2023-06-08 | — | |
| 8-K | 2023-05-11 | 2023-05-08 |
Showing 1–50 of 99 filings
Key facts
CIK
818686
CUSIP
881624209
13F (30d)
498 filings
497 filers
Visit website
Investor relations